Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 May;65(5):1800–1807. doi: 10.1128/iai.65.5.1800-1807.1997

Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

A C Savoy 1, D M Lupan 1, P B Manalo 1, J S Roberts 1, A M Schlageter 1, L C Weinhold 1, T R Kozel 1
PMCID: PMC175220  PMID: 9125564

Abstract

Passive immunization with monoclonal antibodies (MAbs) specific for the major capsular polysaccharide of Cryptococcus neoformans alters the course of murine cryptococcosis. During studies of passive immunization for treatment of murine cryptococcosis, we noted the occurrence of an acute, lethal toxicity. Toxicity was characterized by scratching, lethargy, respiratory distress, collapse, and death within 20 to 60 min after injection of antibody. The toxic effect was observed only in mice with a cryptococcal infection and was reduced or absent in the early and late stages of disease. The clinical course and histopathology were consistent with those for shock. There was considerable variation between mouse strains in susceptibility to toxicity. Swiss Webster mice from the Charles River colony were most susceptible, followed by C3H/He, BALB/c, and C57BL/6 mice. DBA/2 mice and Swiss Webster mice from the Simonsen colony were resistant. Acute toxicity was mimicked by injection of preformed complexes of MAb and purified polysaccharide. The toxic effect was also produced by injection of MAbs into mice that were preloaded with polysaccharide. The toxic effect was not blocked by treatment of mice with chloropheniramine or anti-tumor necrosis factor alpha antibodies or by depletion of complement components via pretreatment with cobra venom factor. Toxicity was reduced by treatment of mice with high doses of epinephrine, dexamethasone, or chlorpromazine. Finally, the toxic effect was completely blocked by treatment of mice with the platelet-activating factor antagonist WEB 2170 BS or by pretreatment of mice with the liposome-encapsulated drug dichloromethylene diphosphonate, a procedure which depletes macrophages from the spleen and liver.

Full Text

The Full Text of this article is available as a PDF (353.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  2. Blackstock R. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J Med Vet Mycol. 1996 Jan-Feb;34(1):19–30. doi: 10.1080/02681219680000041. [DOI] [PubMed] [Google Scholar]
  3. Blackstock R., McCormack J. M., Hall N. K. Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance. Infect Immun. 1987 Jan;55(1):233–239. doi: 10.1128/iai.55.1.233-239.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blackstock R., Zembala M., Asherson G. L. Functional equivalence of cryptococcal and haptene-specific T suppressor factor (TsF). I. Picryl and oxazolone-specific TsF, which inhibit transfer of contact sensitivity, also inhibit phagocytosis by a subset of macrophages. Cell Immunol. 1991 Sep;136(2):435–447. doi: 10.1016/0008-8749(91)90365-i. [DOI] [PubMed] [Google Scholar]
  5. Bleeker W. K., Agterberg J., Rigter G., van Rooijen N., Bakker J. C. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol. 1989 Sep;77(3):338–344. [PMC free article] [PubMed] [Google Scholar]
  6. Brown E. J., Hosea S. W., Frank M. M. The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. J Immunol. 1981 Jun;126(6):2230–2235. [PubMed] [Google Scholar]
  7. Bulmer G. S., Sans M. D. Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J Bacteriol. 1967 Nov;94(5):1480–1483. doi: 10.1128/jb.94.5.1480-1483.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Casadevall A., DeShaw M., Fan M., Dromer F., Kozel T. R., Pirofski L. A. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun. 1994 Sep;62(9):3864–3872. doi: 10.1128/iai.62.9.3864-3872.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Casals-Stenzel J., Heuer H. O. Use of WEB 2086 and WEB 2170 as platelet-activating factor antagonists. Methods Enzymol. 1990;187:455–465. doi: 10.1016/0076-6879(90)87052-5. [DOI] [PubMed] [Google Scholar]
  10. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S3–10. doi: 10.1016/0090-1229(92)90035-m. [DOI] [PubMed] [Google Scholar]
  11. Cherniak R., Morris L. C., Anderson B. C., Meyer S. A. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun. 1991 Jan;59(1):59–64. doi: 10.1128/iai.59.1.59-64.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cochrane C. G., Müller-Eberhard H. J., Aikin B. S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970 Jul;105(1):55–69. [PubMed] [Google Scholar]
  13. Diamond R. D., Allison A. C. Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect Immun. 1976 Sep;14(3):716–720. doi: 10.1128/iai.14.3.716-720.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Diamond R. D., May J. E., Kane M. A., Frank M. M., Bennett J. E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974 Jun;112(6):2260–2270. [PubMed] [Google Scholar]
  15. Doebber T. W., Wu M. S., Biftu T. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731. J Immunol. 1986 Jun 15;136(12):4659–4668. [PubMed] [Google Scholar]
  16. Dong Z. M., Murphy J. W. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest. 1996 Feb 1;97(3):689–698. doi: 10.1172/JCI118466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dromer F., Charreire J., Contrepois A., Carbon C., Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987 Mar;55(3):749–752. doi: 10.1128/iai.55.3.749-752.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dromer F., Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis. 1991 May;163(5):1114–1120. doi: 10.1093/infdis/163.5.1114. [DOI] [PubMed] [Google Scholar]
  19. FOX C. L., Jr, EINBINDER J. M., NELSON C. T. Comparative inhibition of anaphylaxis in mice by steroids, tranquilizers and other drugs. Am J Physiol. 1958 Feb;192(2):241–246. doi: 10.1152/ajplegacy.1958.192.2.241. [DOI] [PubMed] [Google Scholar]
  20. Franks A. K., Kujawa K. I., Yaffe L. J. Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun. 1991 Aug;59(8):2609–2614. doi: 10.1128/iai.59.8.2609-2614.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gadina M., Bertini R., Mengozzi M., Zandalasini M., Mantovani A., Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med. 1991 Jun 1;173(6):1305–1310. doi: 10.1084/jem.173.6.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Galanos C., Freudenberg M. A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939–5943. doi: 10.1073/pnas.76.11.5939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gelfand J. A., Hurley D. L., Fauci A. S., Frank M. M. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis. 1978 Jul;138(1):9–16. doi: 10.1093/infdis/138.1.9. [DOI] [PubMed] [Google Scholar]
  24. Henderson D. K., Bennett J. E., Huber M. A. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest. 1982 May;69(5):1185–1190. doi: 10.1172/JCI110555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Heuer H. O., Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther. 1990 Dec;255(3):962–968. [PubMed] [Google Scholar]
  26. Heuer H. O. Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170). Eur J Pharmacol. 1991 Jun 25;199(2):157–163. doi: 10.1016/0014-2999(91)90453-w. [DOI] [PubMed] [Google Scholar]
  27. Heuer H. O., Letts G., Meade C. J. Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo. J Lipid Mediat. 1990;2 (Suppl):S101–S108. [PubMed] [Google Scholar]
  28. Houpt D. C., Pfrommer G. S., Young B. J., Larson T. A., Kozel T. R. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun. 1994 Jul;62(7):2857–2864. doi: 10.1128/iai.62.7.2857-2864.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kozel T. R., Follette J. L. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun. 1981 Mar;31(3):978–984. doi: 10.1128/iai.31.3.978-984.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kozel T. R., Gotschlich E. C. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol. 1982 Oct;129(4):1675–1680. [PubMed] [Google Scholar]
  31. Kozel T. R., Gulley W. F., Cazin J., Jr Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun. 1977 Dec;18(3):701–707. doi: 10.1128/iai.18.3.701-707.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kozel T. R., Hermerath C. A. Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column. J Immunol Methods. 1988 Feb 24;107(1):53–58. doi: 10.1016/0022-1759(88)90008-7. [DOI] [PubMed] [Google Scholar]
  33. Kozel T. R., Highison B., Stratton C. J. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun. 1984 Feb;43(2):574–579. doi: 10.1128/iai.43.2.574-579.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kozel T. R., McGaw T. G. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun. 1979 Jul;25(1):255–261. doi: 10.1128/iai.25.1.255-261.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mozaffarian N., Berman J. W., Casadevall A. Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells. J Leukoc Biol. 1995 Apr;57(4):657–662. doi: 10.1002/jlb.57.4.657. [DOI] [PubMed] [Google Scholar]
  36. Mukherjee J., Nussbaum G., Scharff M. D., Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med. 1995 Jan 1;181(1):405–409. doi: 10.1084/jem.181.1.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mukherjee J., Pirofski L. A., Scharff M. D., Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3636–3640. doi: 10.1073/pnas.90.8.3636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Mukherjee J., Scharff M. D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun. 1992 Nov;60(11):4534–4541. doi: 10.1128/iai.60.11.4534-4541.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Murphy J. W., Cozad G. C. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun. 1972 Jun;5(6):896–901. doi: 10.1128/iai.5.6.896-901.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Osada S., Ichiki H., Oku H., Ishiguro K., Kunitomo M., Semma M. Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol. 1994 Feb 11;252(3):347–350. doi: 10.1016/0014-2999(94)90185-6. [DOI] [PubMed] [Google Scholar]
  41. Pettoello-Mantovani M., Casadevall A., Kollmann T. R., Rubinstein A., Goldstein H. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet. 1992 Jan 4;339(8784):21–23. doi: 10.1016/0140-6736(92)90142-p. [DOI] [PubMed] [Google Scholar]
  42. ROTH F. E., GOVIER W. M. Comparative pharmacology of chlorpheniramine (Chlor-Trimeton) and its optical isomers. J Pharmacol Exp Ther. 1958 Dec;124(4):347–349. [PubMed] [Google Scholar]
  43. Rao V. S., Fonteles M. C. Involvement of PAF-acether and eicosanoids in adrenaline-induced pulmonary edema in mice. Braz J Med Biol Res. 1991;24(3):319–321. [PubMed] [Google Scholar]
  44. Rhodes J. C. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia. 1985 Jun;23(3):225–234. doi: 10.1080/00362178585380331. [DOI] [PubMed] [Google Scholar]
  45. Rickert D. E., Burke J., Fischer L. J. Cyproheptadine-induced depletion of insulin in the rat. J Pharmacol Exp Ther. 1975 May;193(2):585–593. [PubMed] [Google Scholar]
  46. Rinaldi-Carmona M., Congy C., Pointeau P., Vidal H., Brelière J. C., Le Fur G. Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain. Life Sci. 1994;54(2):119–127. doi: 10.1016/0024-3205(94)00782-9. [DOI] [PubMed] [Google Scholar]
  47. Sanford J. E., Lupan D. M., Schlageter A. M., Kozel T. R. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun. 1990 Jun;58(6):1919–1923. doi: 10.1128/iai.58.6.1919-1923.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Schlageter A. M., Kozel T. R. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun. 1990 Jun;58(6):1914–1918. doi: 10.1128/iai.58.6.1914-1918.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Steinbuch M., Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969 Nov;134(2):279–284. doi: 10.1016/0003-9861(69)90285-9. [DOI] [PubMed] [Google Scholar]
  50. Sun X. M., Hsueh W., Torre-Amione G. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor. Am J Pathol. 1990 Apr;136(4):949–956. [PMC free article] [PubMed] [Google Scholar]
  51. Szabó C., Wu C. C., Mitchell J. A., Gross S. S., Thiemermann C., Vane J. R. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res. 1993 Dec;73(6):991–999. doi: 10.1161/01.res.73.6.991. [DOI] [PubMed] [Google Scholar]
  52. Tarazona R., González-García A., Zamzami N., Marchetti P., Frechin N., Gonzalo J. A., Ruiz-Gayo M., van Rooijen N., Martínez C., Kroemer G. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol. 1995 Jan 15;154(2):861–870. [PubMed] [Google Scholar]
  53. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  54. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994 Sep 14;174(1-2):83–93. doi: 10.1016/0022-1759(94)90012-4. [DOI] [PubMed] [Google Scholar]
  55. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol Methods. 1989 Nov 13;124(1):1–6. doi: 10.1016/0022-1759(89)90178-6. [DOI] [PubMed] [Google Scholar]
  56. Vecchiarelli A., Retini C., Monari C., Tascini C., Bistoni F., Kozel T. R. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun. 1996 Jul;64(7):2846–2849. doi: 10.1128/iai.64.7.2846-2849.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Vecchiarelli A., Retini C., Pietrella D., Monari C., Tascini C., Beccari T., Kozel T. R. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun. 1995 Aug;63(8):2919–2923. doi: 10.1128/iai.63.8.2919-2923.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wlaz P., Rolinski Z., Kleinrok Z., Czuczwar S. J. Influence of chronic aminophylline on the anticonvulsant efficacy of phenobarbital and valproate in mice. Epilepsia. 1993 Mar-Apr;34(2):385–389. doi: 10.1111/j.1528-1157.1993.tb02426.x. [DOI] [PubMed] [Google Scholar]
  59. Yushmanov V. E., Khristianovich D. S., Rozantseva T. V., Sibeldina L. A. NMR estimation of protective effect of insulin on mouse liver with epinephrine-induced metabolic lesions. NMR Biomed. 1991 Aug;4(4):167–172. doi: 10.1002/nbm.1940040403. [DOI] [PubMed] [Google Scholar]
  60. de Boer J. P., Wolbink G. J., Thijs L. G., Baars J. W., Wagstaff J., Hack C. E. Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology. 1992 Sep-Oct;24(2):135–148. doi: 10.1016/0162-3109(92)90019-9. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES